The role of oral fluoropyrimidines in the treatment of advanced gastric cancer

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 4, 2008, Pages 361-366

  Pieters, A ^a   Laurent, S ^a   Dero, I ^a   Van Damme, N ^a   Peeters, Marc ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OXALIPLATIN; PLATINUM COMPLEX; TAXANE DERIVATIVE; TEGAFUR; UFT; URACIL;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTRECTOMY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; REVIEW; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; SYSTEMIC THERAPY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; PYRIMIDINES; STOMACH NEOPLASMS;

EID: 60849134276     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. KELLEY J., DUGGAN J. Gastric cancer epidemiology and risk factors. J. Clin. Epidemiol., 2003, 56: 1-9.
2. ESMO GUIDELINES WORKING GROUP, CUNNINGHAM D. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann. Oncol., 2007, Suppl 2: ii17-18.
3. National Cancer register, Belgium, 2003.
4. HAENSZEL W., KURIHARA M., SEGI M., LOCKE F., SHIMUZU K., SEGI M. Stomach cancer among Japanese in Hawaii. J. Natl. Cancer Inst., 1972, 49: 969-988.
5. PERA M., CAMERON A.J., TRASTEK V.F., CARPENTER H.A., ZINSMEISTER A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterol., 1993, 104: 510-513.
6. RENEHAN A.G., TYSON M., EGGER M., HELLER R.F., ZWAHLEN M. Body-mass index and incidence of cancer: a systemic review and meta-analysis of prospective observational studies. Lancet, 2008, 371: 569-578.
7. GLIMELIUS B., EKSTRÖM K., HOFFMAN K., GRAF W., SJÖDÉN P.O., HAGLUND U., SVENSSON C., ENANDER L.K., LINNÉ T., SELLSTRÖM H., HEUMAN R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol., 1997, 8: 163-168.
8. KIM N., PARK Y.S., HEO D.S., SUH C., KIM S.Y., PARK K.C., KANG Y.K., SHIN D.B., KIM H.J. A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5- fluorouracil alone in the treatment of advanced gastric cancer. Cancer, 1993, 71 (12): 3813-3818.
9. OHTSU A., SHIMADA Y., SHIRAO K., BOKU N., HYODO I., SAITO H., YAMAMICHI N., MIYATA Y., IKEDA N., YAMAMOTO S., FUKUDA H., YOSHIDA S. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology Group study (JCOG9205). J. Clin. Oncol., 2003, 21 (1): 54-59.
10. VANHOEFER U., ROUGIER P., WILKE H., DUCREUX M.P., LACAVE A.J., VAN CUTSEM E., PLANKER M., SANTOS J.G., PIEDBOIS P., PAILLOT B., BODENSTEIN H., SCHMOLL H.J., BLEIBERG H., NORDLINGER B., COUVREUR M.L., BARON B., WILS J.A. Final results of a randomized Phase III trial to sequential high dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol., 2000, 18 (14): 2648-2657.
11. LUTZ M., WILKE H., WAGENER D., VANHOEFER U., JEZIORSKI K., HEGEWISCH-BECKER S., BALLEISEN L., JOOSSEN E., JANSEN R.L., DEBOIS M., BETHE U., PRAET M., WILS J., VAN CUTSEM E. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschapft Internistische Onkologie. J. Clin. Oncol., 2007, 25 (18): 2580-2585.
12. WATERS J., NORMAN A., CUNNINGHAM D., SCARFFE I., WEBB A., HARPER P., JOFFE J., MACKEAN M., MANSI J., LEAHY M., HILL A., OATES J., RAO S., NICOLSON M., HICKISH T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. B. J. Cancer, 1999, 80: 269-272.
13. WEBB A., CUNNINGHAM D., SCARFFE J.H., HARPER P., NORMAN A., JOFFE J.K., HUGHES M., MANSI J., FINDLAY M., HILL A., OATES J., NICOLSON M., HICKISH T., O'BRIEN M., IVESON T., WATSON M., UNDERHILL C., WARDLEY A., MEEHAN M. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol., 1997, 15: 261-267.
14. ROSS P., NICOLSON M., CUNNINGHAM D., VALLE J., SEYMOUR M., HARPER P., PRICE T., ANDERSON H., IVESON T., HICKISH T., LOFTS F., NORMAN A. Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI-5FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol., 2002, 20 (8): 1996-2004.
15. WAGNER A., GROTHE W., HAERTING J., KLEBER G., GROTHEY A., FLEIG WE. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J. Clin. Oncol., 2006, 24 (18): 2903-2909.
16. VAN CUTSEM E., MOISEYENKO V., TJULANDIN S., MAJILIS A., CONSTENLA M., CORRADO B., RODRIGUES A., FODOR M., CHAO Y., VOZNYI E., RISSE M., AJANI J. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol., 2006, 24 (31): 4991-4997.
17. DANK M., ZALUSKI J., BARONE C., VALVERE V., YALCIN S., PESCHEL S., WENCZL M., GOKER E., CISAR L., WANG K., BUGAT R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol., 2008, 19: 1450-1457.
18. AL-BATRAN S., HARTMANN J.T., PROBST S., SCHMALENBERG H., HOLLERBACH S., HOFHEINZ R., RETHWISCH V., SEIPELT G., HOMANN N., WILHELM G., SCHUCH G., STOEHLMACHER J., DERIGS H.G., HEGEWISCH-BECKER S., GROSSMANN I., PAULIGK C., ATMACA A., BOKEMEYER C., KNUTH A., JÄGER E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol., 2008, 26 (9): 1435-1442.
19. DHILLON S., SCOTT L.J. Capecitabine in advanced gastric cancer or oesophagogastric cancer. Drugs, 2007, 67 (4): 601-610.
20. OKINES A., CHAU I., CUNNINGHAM D. Capecitabine in advanced gastric cancer. Expert. Opin. Pharmacother., 2007, 8 (16): 2851-2861.
21. CUNNINGHAM D., STARLING N., RAO S., IVESON T., NICOLSON M., COXON F., MIDDLETON G., DANIEL F., OATES J., NORMAN A.R., UPPER GASTROINTESTINAL CLINICAL STUDIES GROUP OF THE NATIONAL CANCER RESEARCH INSTITUTE OF THE UNITED KINGDOM. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med., 2008, 358 (1): 36-46.
22. KANG Y., KANG W., SHIN D., CHEN J., XIONG J., WANG J., LICHINITSER M., SALAS M., SUAREZ T., SANTAMARIA J. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J. Clin. Oncol., 2006, 24 (18 Suppl.): Abstr. LBA4018.
23. SHOFFSKI P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs, 2004, 15 (2): 85-106.
24. BOKU N., YAMAMOTO S., SHIRAO K., DOI T., SAWAKI A., KOIZUMI W., SAITO H., YAMAGUCHI K., KIMURA A., OHTSU A. Randomized Phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J. Clin. Oncol., 2007, 25 (18 Suppl): Abstr. LBA4513.
25. KOIZUMI W., NARAHARA H., HARA T., TAKAGANE A., AKIYA T., TAKAGI M., MIYASHITA K., NISHIZAKI T., KOBAYASHI O., TAKIYAMA W., TOH Y., NAGAIE T., TAKAGI S., YAMAMURA Y., YANAOKA K., ORITA H., TAKEUCHI M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS TRIAL): a phase III trial. Lancet Oncol., 2008, 9 (3): 215-221.
26. SAKURAMOTO S., SASAKO M., YAMAGUCHI T., KINOSHITA T., FUJII M., NASHIMOTO A., FURUKAWA H., NAKAJIMA T., OHASHI Y., IMAMURA H., HIGASHINO M., YAMAMURA Y., KURITA A., ARAI K., ACTS-GC GROUP. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med., 2007, 357: 1810-1820.
27. TWELVES C., GOLLINS S., GRIEVE R., SAMUEL L. A randomised cross over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann. Oncol., 2006, 17: 239-245.
28. PFEIFFER P., MORTENSEN J., BJERREGAARD B., ECKHOFF L., SCHONNEMAN K., SANDBERG E., AABO K., JAKOBSEN A. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J. Cancer, 2006, 42 (16): 2738-2743.
29. BORNER M., SCHOFFSKI P., DE WIT R., CAPONIGRO F., COMELLA G., SULKES A., GREIM G., PETERS G.J., VAN DER BORN K., WANDERS J., DE BOER R., MARTIN C., FUMOLEAU P. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur. J. Cancer, 2002, 38 (3): 349-358.